Studies have found that stromal cells in the myeloma microenvironment could inhibit miRNA-15a/-16 expression in bone marrow cells by secreting high levels of the inflammatory factor IL-6, thus weakening the inhibitory effects on tumor cell proliferation and participating in the occurrence of drug resistance in myeloma. The gene discussed is IL6; the disease is plasma cell myeloma.